Clinical and Translational Oncology

, Volume 16, Issue 5, pp 476–487 | Cite as

Observations on the effects of Suppressor of Cytokine Signaling 7 (SOCS7) knockdown in breast cancer cells: their in vitro response to Insulin Like Growth Factor I (IGF-I)

  • W. SasiEmail author
  • L. Ye
  • W. G. Jiang
  • K. Mokbel
  • A. Sharma
Research Article



Suppressor of cytokine signaling 7 (SOCS7) is a member of the SOCS family and is known to interact with phospholipase Cγ-1 (PLCγ-1), one of the insulin-like growth factor-I (IGF-I) receptor downstream molecules. In this study, we sought to observe the effect of knocking down SOCS7 gene on breast cancer cells in vitro growth and migration and to elucidate whether this involves IGF-I-PLCγ1 route using the PLCγ-1 blocker U73122.


Suitable breast cancer cells (MCF7 and MDA-MB-231) were transfected with anti-SOCS7 ribozymal transgene, to create sub-lines with SOCS7 knockdown verified by RT-PCR. The growth and migration of the cells were evaluated in the presence or absence of IGF-I and PLCγ-1 inhibitor using growth assay, scratch-wound and electrical cell impedance sensing (ECIS) migration assays.


IGF-I treatment produced more pronounced influence on MCF7 growth and migration and on MDA-MB-231 migration when SOCS7 gene was knocked down in both lines (p < 0.05). The absence of IGF-I-induced growth response in MDA-MB-231 could be due to the intrinsic characteristics of these cells. PLCγ-1 pharmacological inhibition during their in vitro migration seemed to only occur when SOCS7 gene was knocked down.


To the best of our knowledge, this is the first report of the SOCS7 regulatory role in IGF-I induced in vitro functions in ER-positive and ER-negative breast cancer cells. IGF-I treatment and SOCS7 loss have synergistically resulted in increased growth and migration of MCF7 and in increased migration of MDA-MB-231 cells. The migratory effects could be due to a precise anti-PLCγ-1 role.


Insulin-like growth factor-I Suppressor of cytokine signaling Phospholipase Cγ-1 Breast cancer 


Conflict of interest



  1. 1.
    Backer JM, Myers MG, Shoelson SE, Chin DJ, Sun XJ, Miralpeix M, et al. Phosphatidylinositol 3′-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J. 1992;11:3469–79.PubMedCentralPubMedGoogle Scholar
  2. 2.
    White MF. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem. 1998;182:3–11.PubMedCrossRefGoogle Scholar
  3. 3.
    Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Investig. 1994;93:1266–74.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Abedi H, Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem. 1997;272:15442–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Wells A, Grandis JR. Phospholipase C-gamma1 in tumor progression. Clin Exp Metastasis. 2003;20:285–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G, Page DL. Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci USA. 1991;88:10435–9.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Pollak M, Beamer W, Zhang JC. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev. 1998;17:383–90.PubMedCrossRefGoogle Scholar
  8. 8.
    Kassis J, Moellinger J, Lo H, Greenberg NM, Kim HG, Wells A. A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. Clin Cancer Res. 1999;5:2251–60.PubMedGoogle Scholar
  9. 9.
    Wauman J, De Smet AS, Catteeuw D, Belsham D, Tavernier J. Insulin receptor substrate 4 couples the leptin receptor to multiple signaling pathways. Mol Endocrinol. 2008;22:965–77.PubMedCrossRefGoogle Scholar
  10. 10.
    Pazienza V, Vinciguerra M, Andriulli A, Mangia A. Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells. J Gen Virol. 2010;91:1678–86.PubMedCrossRefGoogle Scholar
  11. 11.
    Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002;277:42394–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Krebs DL, Uren RT, Metcalf D, Rakar S, Zhang JG, Starr R, et al. SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol Cell Biol. 2002;22:4567–78.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Kremer BE, Adang LA, Macara IG. Septins regulate actin organization and cell-cycle arrest through nuclear accumulation of NCK mediated by SOCS7. Cell. 2007;130:837–50.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Matuoka K, Miki H, Takahashi K, Takenawa T. A novel ligand for an SH3 domain of the adaptor protein Nck bears an SH2 domain and nuclear signaling motifs. Biochem Biophys Res Commun. 1997;239:488–92.PubMedCrossRefGoogle Scholar
  15. 15.
    Nishimura R, Li W, Kashishian A, Mondino A, Zhou M, Cooper J, et al. Two signaling molecules share a phosphotyrosine-containing binding site in the platelet-derived growth factor receptor. Mol Cell Biol. 1993;13:6889–96.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Lettau M, Pieper J, Janssen O. Nck adapter proteins: functional versatility in T cells. Cell Commun Signal. 2009;7:1.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Lee CH, Li W, Nishimura R, Zhou M, Batzer AG, Myers MG Jr, et al. Nck associates with the SH2 domain-docking protein IRS-1 in insulin-stimulated cells. Proc Natl Acad Sci USA. 1993;90:11713–7.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Amoui M, Craddock BP, Miller WT. Differential phosphorylation of IRS-1 by insulin and insulin-like growth factor I receptors in Chinese hamster ovary cells. J Endocrinol. 2001;171:153–62.PubMedCrossRefGoogle Scholar
  19. 19.
    Hu Q, Milfay D, Williams LT. Binding of NCK to SOS and activation of ras-dependent gene expression. Mol Cell Biol. 1995;15:1169–74.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Knisz J, Banks A, McKeag L, Metcalfe DD, Rothman PB, Brown JM. Loss of SOCS7 in mice results in severe cutaneous disease and increased mast cell activation. Clin Immunol. 2009;132:277–84.PubMedCrossRefGoogle Scholar
  21. 21.
    Martens N, Uzan G, Wery M, Hooghe R, Hooghe-Peters EL, Gertler A. Suppressor of cytokine signaling 7 inhibits prolactin, growth hormone, and leptin signaling by interacting with STAT5 or STAT3 and attenuating their nuclear translocation. J Biol Chem. 2005;280:13817–23.PubMedCrossRefGoogle Scholar
  22. 22.
    Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, et al. Molecular targeting of matrilysin and its impact on tumour growth in vivo, the potential implications in breast cancer therapy. Clin Cancer Res. 2005;11:6012–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Keese CR, Wegener J, Walker SR, Giaever I. Electrical wound-healing assay for cells in vitro. Proc Natl Acad Sci USA. 2004;101:1554–9.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Pollak MN, Polychronakos C, Yousefi S, Richard M. Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. Biochem Biophys Res Commun. 1988;154:326–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, Allred DC, et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Investig. 1989;84:1418–23.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Jackson JG, White MF, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem. 1998;273:9994–10003.PubMedCrossRefGoogle Scholar
  27. 27.
    Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, Mayer D. Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer. 2000;89:506–13.PubMedCrossRefGoogle Scholar
  28. 28.
    Surmacz E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia. 2000;5:95–105.PubMedCrossRefGoogle Scholar
  29. 29.
    Bartucci M, Morelli C, Mauro L, Ando S, Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res. 2001;61:6747–54.PubMedGoogle Scholar
  30. 30.
    Bartella V, De Marco P, Malaguamera R, Belfiore A, Maggiolini M. New advances on the functional cross-talk between insulin like growth factor-I and estrogen signaling in cancer. Cell Signal. 2012;24:1515–21.PubMedCrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2013

Authors and Affiliations

  • W. Sasi
    • 1
    Email author
  • L. Ye
    • 2
  • W. G. Jiang
    • 2
  • K. Mokbel
    • 1
    • 3
  • A. Sharma
    • 1
  1. 1.St George’s, University of London, Cranmer TerraceLondonUK
  2. 2.Cardiff UniversityCardiffUK
  3. 3.The London Breast InstituteThe Princess Grace HospitalLondonUK

Personalised recommendations